Concept Life Sciences adds to its team

Integrated drug discovery, development and analytical services company Concept Life Sciences has appointed Matilda Bingham as site director of its Alderley Park unit based in Cheshire, UK.

With over 15 years’ experience in the pharmaceutical industry in both biotech and pharma environments, Bingham joins Concept from Rex Pharma, where she held positions as head of research operations and executive director of oncology and immunology.

Prior to this, Bingham has also previously worked for MSD Research Laboratories.

She said: “I am looking forward to applying my own drug discovery experience alongside the already established expertise within the team to expand integrated drug discovery services at Concept, both at the Alderley Park Site and in collaboration with the Company’s other sites.”

Additionally, David Higton joins Concept as its biotransformation and metabolite identification expert.

Higton, who has over 34 years of expertise in bioanalytical and biotransformation studies, has spent 23 years at Glaxo Group Research – now GlaxoSmithKline – where he supported pre-clinical, clinical and discovery investigations for both non-GLP and GLP studies.

He most recently held the role of head of analytical sciences at Cyprotex and prior to this, he was analytical team leader at Redx Pharma.

Higton has also held roles for AstraZeneca and Xceleron.

Phillip Payne, chief operating officer at Concept Life Sciences, said: “With several years’ experience of managing multidisciplinary research projects in a pharmaceutical company environment, we are delighted to have appointed Matilda to head up our new Alderley Park site.

“We are also pleased to welcome David, whose expertise will be a valuable addition to the analytical team.”